NCT02881853View on ClinicalTrials.gov

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 17, 2016

Primary Completion Date

February 24, 2017

Study Completion Date

February 24, 2017

Conditions
Healthy VolunteersAtopic Disease
Interventions
DRUG

XmAb7195

DRUG

Placebo

Trial Locations (1)

78209

ICON Early Phase Services, LLC, San Antonio

All Listed Sponsors
collaborator

ICON Early Phase Services, LLC

UNKNOWN

lead

Xencor, Inc.

INDUSTRY

NCT02881853 - Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 | Biotech Hunter | Biotech Hunter